{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:56:49Z","timestamp":1780628209328,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00115-024-01647-z","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T11:02:01Z","timestamp":1712142121000},"page":"416-422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Klinisches Management der therapieresistenten Depression","Clinical management of treatment-resistant depression"],"prefix":"10.1007","volume":"95","author":[{"given":"Bernhard T.","family":"Baune","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Fromme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Kiebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Hurlemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"1647_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1515\/hmbci-2022-0042","volume":"44","author":"M Ali","year":"2023","unstructured":"Ali\u00a0M, Ullah\u00a0I, Diwan\u00a0MN et\u00a0al (2023) Zuranolone and its role in treating major depressive disorder: a\u00a0narrative review. Horm Mol Biol Clin Investig 44:229\u2013236. https:\/\/doi.org\/10.1515\/hmbci-2022-0042","journal-title":"Horm Mol Biol Clin Investig"},{"key":"1647_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","volume":"20","author":"L Bartova","year":"2019","unstructured":"Bartova\u00a0L, Dold\u00a0M, Kautzky\u00a0A et\u00a0al (2019) Results of the European Group for the Study of Resistant Depression (GSRD)\u2014basis for further research and clinical practice. World J Biol Psychiatry 20:427\u2013448. https:\/\/doi.org\/10.1080\/15622975.2019.1635270","journal-title":"World J Biol Psychiatry"},{"key":"1647_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0004867418824026","volume":"53","author":"BT Baune","year":"2019","unstructured":"Baune\u00a0BT, Boyce\u00a0P, Morris\u00a0G et\u00a0al (2019) Organising the front line: Is there a\u00a0rationale for the first-line pharmacotherapy of major depressive disorder? Aust N Z J Psychiatry 53:279\u2013281. https:\/\/doi.org\/10.1177\/0004867418824026","journal-title":"Aust N Z J Psychiatry"},{"key":"1647_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.euroneuro.2021.07.092","volume":"53","author":"BT Baune","year":"2021","unstructured":"Baune\u00a0BT, Sampson\u00a0E, Louise\u00a0J et\u00a0al (2021) No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A\u00a06-week double-blind placebo controlled randomized trial. Eur Neuropsychopharmacol 53:34\u201346. https:\/\/doi.org\/10.1016\/j.euroneuro.2021.07.092","journal-title":"Eur Neuropsychopharmacol"},{"key":"1647_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jad.2018.04.016","volume":"235","author":"IO Bergfeld","year":"2018","unstructured":"Bergfeld\u00a0IO, Mantione\u00a0M, Figee\u00a0M et\u00a0al (2018) Treatment-resistant depression and suicidality. J\u00a0Affect Disord 235:362\u2013367. https:\/\/doi.org\/10.1016\/j.jad.2018.04.016","journal-title":"J Affect Disord"},{"key":"1647_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.neuron.2020.06.002","volume":"107","author":"E Beurel","year":"2020","unstructured":"Beurel\u00a0E, Toups\u00a0M, Nemeroff\u00a0CB (2020) The Bidirectional Relationship of Depression and Inflammation: Double Trouble. Neuron 107:234\u2013256. https:\/\/doi.org\/10.1016\/j.neuron.2020.06.002","journal-title":"Neuron"},{"key":"1647_CR7","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bph.15753","volume":"179","author":"\u00c9 Borb\u00e9ly","year":"2022","unstructured":"Borb\u00e9ly \u00c9, Simon\u00a0M, Fuchs\u00a0E et\u00a0al (2022) Novel drug developmental strategies for treatment-resistant depression. British J Pharmacology 179:1146\u20131186. https:\/\/doi.org\/10.1111\/bph.15753","journal-title":"British J Pharmacology"},{"key":"1647_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2017.00039","author":"A-K Brem","year":"2017","unstructured":"Brem\u00a0A\u2011K, Lehto\u00a0SM (2017) Stuck between Bench and Bedside: Why Non-invasive Brain Stimulation Is Not Accessible to Depressed Patients in Europe. Front Hum Neurosci. https:\/\/doi.org\/10.3389\/fnhum.2017.00039","journal-title":"Front Hum Neurosci"},{"key":"1647_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1177\/0706743719828965","volume":"64","author":"S Brown","year":"2019","unstructured":"Brown\u00a0S, Rittenbach\u00a0K, Cheung\u00a0S et\u00a0al (2019) Current and Common Definitions of Treatment-Resistant Depression: Findings from a\u00a0Systematic Review and Qualitative Interviews. Can J Psychiatry 64:380\u2013387. https:\/\/doi.org\/10.1177\/0706743719828965","journal-title":"Can J Psychiatry"},{"key":"1647_CR10","volume-title":"Nationale Versorgungs Leitlinie Unipolare Depression. Leitlinien.de","author":"Bundes\u00e4rztekammer","year":"2022","unstructured":"Bundes\u00e4rztekammer, Kassen\u00e4rztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2022) Nationale Versorgungs Leitlinie Unipolare Depression. Leitlinien.de"},{"key":"1647_CR11","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris\u00a0R, Giribaldi\u00a0B, Watts\u00a0R et\u00a0al (2021) Trial of Psilocybin versus Escitalopram for Depression. N\u00a0Engl J Med 384:1402\u20131411. https:\/\/doi.org\/10.1056\/NEJMoa2032994","journal-title":"N Engl J Med"},{"key":"1647_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000357500","volume":"83","author":"AF Carvalho","year":"2014","unstructured":"Carvalho\u00a0AF, Berk\u00a0M, Hyphantis\u00a0TN, McIntyre\u00a0RS (2014) The Integrative Management of Treatment-Resistant Depression: A\u00a0Comprehensive Review and Perspectives. Psychother Psychosom 83:70\u201388. https:\/\/doi.org\/10.1159\/000357500","journal-title":"Psychother Psychosom"},{"key":"1647_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly\u00a0EJ, Singh\u00a0JB, Fedgchin\u00a0M et\u00a0al (2018) Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A\u00a0Randomized Clinical Trial. JAMA Psychiatry 75:139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.3739","journal-title":"JAMA Psychiatry"},{"key":"1647_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/bs13040297","volume":"13","author":"JJ Dawood Hristova","year":"2023","unstructured":"Dawood Hristova\u00a0JJ, P\u00e9rez-Jover\u00a0V (2023) Psychotherapy with Psilocybin for Depression: Systematic Review. Behav Sci 13:297. https:\/\/doi.org\/10.3390\/bs13040297","journal-title":"Behav Sci"},{"key":"1647_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1523\/JNEUROSCI.0984-22.2022","volume":"43","author":"S Dutheil","year":"2023","unstructured":"Dutheil\u00a0S, Watson\u00a0LS, Davis\u00a0RE, Snyder\u00a0GL (2023) Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation. J\u00a0Neurosci 43:863\u2013877. https:\/\/doi.org\/10.1523\/JNEUROSCI.0984-22.2022","journal-title":"J Neurosci"},{"key":"1647_CR16","doi-asserted-by":"publisher","DOI":"10.31234\/osf.io\/ak6gx","volume-title":"History repeating: A\u00a0roadmap to address common problems in psychedelic science","author":"M van Elk","year":"2023","unstructured":"van Elk\u00a0M, Fried\u00a0EI (2023) History repeating: A\u00a0roadmap to address common problems in psychedelic science https:\/\/doi.org\/10.31234\/osf.io\/ak6gx"},{"key":"1647_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jad.2022.09.143","volume":"320","author":"CN Epperson","year":"2023","unstructured":"Epperson\u00a0CN, Rubinow\u00a0DR, Meltzer-Brody\u00a0S et\u00a0al (2023) Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3\u00a0double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. J\u00a0Affect Disord 320:353\u2013359. https:\/\/doi.org\/10.1016\/j.jad.2022.09.143","journal-title":"J Affect Disord"},{"key":"1647_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1056\/NEJMra2034954","volume":"386","author":"RT Espinoza","year":"2022","unstructured":"Espinoza\u00a0RT, Kellner\u00a0CH (2022) Electroconvulsive Therapy. N\u00a0Engl J Med 386:667\u2013672. https:\/\/doi.org\/10.1056\/NEJMra2034954","journal-title":"N Engl J Med"},{"key":"1647_CR19","volume-title":"Clinical investigation of medicinal products in the treatment of depression\u2014Scientific guideline","author":"European Medicines Agency","year":"2018","unstructured":"European Medicines Agency (2018) Clinical investigation of medicinal products in the treatment of depression\u2014Scientific guideline. European Medicines Agency, Amsterdam"},{"key":"1647_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1176\/appi.ajp.2021.21020197","volume":"179","author":"M Fava","year":"2022","unstructured":"Fava\u00a0M, Stahl\u00a0S, Pani\u00a0L et\u00a0al (2022) REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A\u00a0Phase\u00a02a Randomized Double-Blind Trial. Am J Psychiatry 179:122\u2013131. https:\/\/doi.org\/10.1176\/appi.ajp.2021.21020197","journal-title":"Am J Psychiatry"},{"key":"1647_CR21","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin\u00a0GM, Aaronson\u00a0ST, Alvarez\u00a0O et\u00a0al (2022) Single-Dose Psilocybin for a\u00a0Treatment-Resistant Episode of Major Depression. N\u00a0Engl J Med 387:1637\u20131648. https:\/\/doi.org\/10.1056\/NEJMoa2206443","journal-title":"N Engl J Med"},{"key":"1647_CR22","doi-asserted-by":"publisher","first-page":"e2230367","DOI":"10.1001\/jamanetworkopen.2022.30367","volume":"5","author":"J Hellmann-Regen","year":"2022","unstructured":"Hellmann-Regen\u00a0J, Clemens\u00a0V, Gr\u00f6zinger\u00a0M et\u00a0al (2022) Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A\u00a0Randomized Clinical Trial. JAMA Netw Open 5:e2230367. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.30367","journal-title":"JAMA Netw Open"},{"key":"1647_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/hup.470080510","volume":"8","author":"G H\u00f6flich","year":"1993","unstructured":"H\u00f6flich\u00a0G, Kasper\u00a0S, Hufnagel\u00a0A et\u00a0al (1993) Application of transcranial magnetic stimulation in treatment of drug-resistant major depression\u2014a report of two cases. Hum Psychopharmacol 8:361\u2013365. https:\/\/doi.org\/10.1002\/hup.470080510","journal-title":"Hum Psychopharmacol"},{"key":"1647_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","volume":"27","author":"OD Howes","year":"2022","unstructured":"Howes\u00a0OD, Thase\u00a0ME, Pillinger\u00a0T (2022) Treatment resistance in psychiatry: state of the art and new directions. Mol Psychiatry 27:58\u201372. https:\/\/doi.org\/10.1038\/s41380-021-01200-3","journal-title":"Mol Psychiatry"},{"key":"1647_CR25","doi-asserted-by":"publisher","first-page":"21m14345","DOI":"10.4088\/JCP.21m14345","volume":"83","author":"DV Iosifescu","year":"2022","unstructured":"Iosifescu\u00a0DV, Jones\u00a0A, O\u2019Gorman\u00a0C et\u00a0al (2022) Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A\u00a0Phase\u00a03 Randomized Clinical Trial (GEMINI). J\u00a0Clin Psychiatry 83:21m14345. https:\/\/doi.org\/10.4088\/JCP.21m14345","journal-title":"J Clin Psychiatry"},{"key":"1647_CR26","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/da.22746","volume":"35","author":"S Kisely","year":"2018","unstructured":"Kisely\u00a0S, Li\u00a0A, Warren\u00a0N, Siskind\u00a0D (2018) A systematic review and meta-analysis of deep brain stimulation for depression. Depress Anxiety 35:468\u2013480. https:\/\/doi.org\/10.1002\/da.22746","journal-title":"Depress Anxiety"},{"key":"1647_CR27","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jamapsychiatry.2014.1611","volume":"71","author":"O K\u00f6hler","year":"2014","unstructured":"K\u00f6hler\u00a0O, Benros\u00a0ME, Nordentoft\u00a0M et\u00a0al (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a\u00a0systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 71:1381\u20131391. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.1611","journal-title":"JAMA Psychiatry"},{"key":"1647_CR28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.neurom.2021.12.010","volume":"25","author":"C Kraus","year":"2022","unstructured":"Kraus\u00a0C, Quach\u00a0D, Sholtes\u00a0DM et\u00a0al (2022) Setting Up a\u00a0Successful Vagus Nerve Stimulation Service for Patients With Difficult-to-Treat Depression. Neuromodulation: Technol At Neural Interface 25:316\u2013326. https:\/\/doi.org\/10.1016\/j.neurom.2021.12.010","journal-title":"Neuromodulation: Technol At Neural Interface"},{"key":"1647_CR29","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41591-020-0806-7","volume":"26","author":"AD Krystal","year":"2020","unstructured":"Krystal\u00a0AD, Pizzagalli\u00a0DA, Smoski\u00a0M et\u00a0al (2020) A randomized proof-of-mechanism trial applying the \u201cfast-fail\u201d approach to evaluating \u03ba\u2011opioid antagonism as a\u00a0treatment for anhedonia. Nat Med 26:760\u2013768. https:\/\/doi.org\/10.1038\/s41591-020-0806-7","journal-title":"Nat Med"},{"key":"1647_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0140-6736(22)02080-3","volume":"401","author":"S Marwaha","year":"2023","unstructured":"Marwaha\u00a0S, Palmer\u00a0E, Suppes\u00a0T et\u00a0al (2023) Novel and emerging treatments for major depression. Lancet 401:141\u2013153. https:\/\/doi.org\/10.1016\/S0140-6736(22)02080-3","journal-title":"Lancet"},{"key":"1647_CR31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre\u00a0RS, Alsuwaidan\u00a0M, Baune\u00a0BT et\u00a0al (2023) Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry 22:394\u2013412. https:\/\/doi.org\/10.1002\/wps.21120","journal-title":"World Psychiatry"},{"key":"1647_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","volume":"156","author":"RS McIntyre","year":"2014","unstructured":"McIntyre\u00a0RS, Filteau\u00a0M\u2011J, Martin\u00a0L et\u00a0al (2014) Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. J\u00a0Affect Disord 156:1\u20137. https:\/\/doi.org\/10.1016\/j.jad.2013.10.043","journal-title":"J Affect Disord"},{"key":"1647_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4176825","volume":"2017","author":"JA Murphy","year":"2017","unstructured":"Murphy\u00a0JA, Sarris\u00a0J, Byrne\u00a0GJ (2017) A Review of the Conceptualisation and Risk Factors Associated with Treatment-Resistant Depression. Depress Res Treat 2017:1\u201310. https:\/\/doi.org\/10.1155\/2017\/4176825","journal-title":"Depress Res Treat"},{"key":"1647_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1079","author":"J Mutz","year":"2019","unstructured":"Mutz\u00a0J, Vipulananthan\u00a0V, Carter\u00a0B et\u00a0al (2019) Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. https:\/\/doi.org\/10.1136\/bmj.l1079","journal-title":"BMJ"},{"key":"1647_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison\u00a0CL, Sanacora\u00a0G, Woolley\u00a0J et\u00a0al (2023) Single-Dose Psilocybin Treatment for Major Depressive Disorder: A\u00a0Randomized Clinical Trial. JAMA 330:843\u2013853. https:\/\/doi.org\/10.1001\/jama.2023.14530","journal-title":"JAMA"},{"key":"1647_CR36","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00115-022-01282-6","volume":"93","author":"C Reif-Leonhard","year":"2022","unstructured":"Reif-Leonhard\u00a0C, Reif\u00a0A, Baune\u00a0BT, Kavakbasi\u00a0E (2022) Vagusnervstimulation bei schwer zu behandelnden Depressionen. Nervenarzt 93:921\u2013930. https:\/\/doi.org\/10.1007\/s00115-022-01282-6","journal-title":"Nervenarzt"},{"key":"1647_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jad.2011.02.020","volume":"137","author":"HG Ruh\u00e9","year":"2012","unstructured":"Ruh\u00e9\u00a0HG, Van Rooijen\u00a0G, Spijker\u00a0J et\u00a0al (2012) Staging methods for treatment resistant depression. A\u00a0systematic review. J\u00a0Affect Disord 137:35\u201345. https:\/\/doi.org\/10.1016\/j.jad.2011.02.020","journal-title":"J Affect Disord"},{"key":"1647_CR38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/0004867418808585","volume":"53","author":"AJ Rush","year":"2019","unstructured":"Rush\u00a0AJ, Aaronson\u00a0ST, Demyttenaere\u00a0K (2019) Difficult-to-treat depression: A\u00a0clinical and research roadmap for when remission is elusive. Aust N Z J Psychiatry 53:109\u2013118. https:\/\/doi.org\/10.1177\/0004867418808585","journal-title":"Aust N Z J Psychiatry"},{"key":"1647_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1055\/a-1714-9097","volume":"55","author":"H Sakurai","year":"2022","unstructured":"Sakurai\u00a0H, Yonezawa\u00a0K, Tani\u00a0H et\u00a0al (2022) Novel Antidepressants in the Pipeline (Phase\u00a0II and\u00a0III): A\u00a0Systematic Review of the US Clinical Trials Registry. Pharmacopsychiatry 55:193\u2013202. https:\/\/doi.org\/10.1055\/a-1714-9097","journal-title":"Pharmacopsychiatry"},{"key":"1647_CR40","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/ijnp\/pyab050","volume":"24","author":"A Savitz","year":"2021","unstructured":"Savitz\u00a0A, Wajs\u00a0E, Zhang\u00a0Y et\u00a0al (2021) Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A\u00a0Phase\u00a02b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study. Int J Neuropsychopharmacol 24:965\u2013976. https:\/\/doi.org\/10.1093\/ijnp\/pyab050","journal-title":"Int J Neuropsychopharmacol"},{"key":"1647_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/wps.21134","volume":"22","author":"ME Thase","year":"2023","unstructured":"Thase\u00a0ME (2023) Recent developments pertaining to treatment-resistant depression: a\u00a040-year perspective. World Psychiatry 22:413\u2013414. https:\/\/doi.org\/10.1002\/wps.21134","journal-title":"World Psychiatry"},{"key":"1647_CR42","volume-title":"Major depressive disorder: developing drugs for treatmen","author":"U.S. Food and Drug Administration.","year":"2018","unstructured":"U.S. Food and Drug Administration., Center for Drug Evaluation and Research (2018) Major depressive disorder: developing drugs for treatmen. U.S. Food and Drug Administration, Silver Spring"},{"key":"1647_CR43","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/wps.21138","volume":"22","author":"P Cuijpers","year":"2023","unstructured":"Cuijpers\u00a0P (2023) From treatment resistance to sequential treatments of depression. World Psychiatry 22:418\u2013419. https:\/\/doi.org\/10.1002\/wps.21138","journal-title":"World Psychiatry"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01647-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-024-01647-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01647-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T10:03:43Z","timestamp":1714730623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-024-01647-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1647"],"URL":"https:\/\/doi.org\/10.1007\/s00115-024-01647-z","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"27 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.T.\u00a0Baune erh\u00e4lt Referenten- und Beraterhonorare von AstraZeneca, Lundbeck, Pfizer, Takeda, Servier, Bristol Myers Squibb, Otsuka, LivaNova, Sunovion, Biogen, Sumitomo Dainippon Pharma, Janssen-Cilag und Boehringer Ingelheim. R.\u00a0Hurlemann erh\u00e4lt Referenten- und Beraterhonorare von Boehringer Ingelheim, Janssen-Cilag und Rovi. S.E.\u00a0Fromme und M.\u00a0Kiebs geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}